India expresses concern about novel coronavirus pneumonia safety in mercad

India expresses concern about novel coronavirus pneumonia safety in mercad On Wednesday local time, the head of India’s major medical research institutions said that there were “major safety problems” in molnupiravir, the new crown oral drug of MSD, or it would prevent it from joining the country’s virus treatment list. It is reported that molnupiravir, an oral drug of mosadon, eventually prevents virus replication by introducing different mechanisms into genetic material, but it may affect growing human cells. Last week, the Indian drug regulatory agency has granted molnupiravir emergency use authorization to MSD, but Balram Bhargava, director general…

The US FDA has urgently authorized Pfizer and MSD anti Novel COVID-19 oral drugs to go on the market

The US FDA has urgently authorized Pfizer and MSD anti Novel COVID-19 oral drugs to go on the market In December 22nd, novel coronavirus pneumonia Paxlovid was approved by the US Food and Drug Administration (FDA). The emergency use authorization of Pfizer was applied within 5 days after symptoms appeared. It was used to treat severe acute lung cancer patients aged 12 and above. Meanwhile, novel coronavirus pneumonia was used by FDA to authorize the use of mercad Molnupiravir in December 23rd. It is the second newly approved oral medicine for patients with high risk and no other…

China’s first anti COVID-19 specific drug was approved for sale, effective for many variants such as delta

This approval is based on the phase 3 clinical trial of activ-2 supported by the National Institutes of Health (NIH), including the positive interim and final results of 847 enrolled patients. The final results showed that compared with placebo, ambacizumab / romisizumab combination therapy could reduce the risk of hospitalization and death in high-risk new crown outpatients by 80% (the interim result was 78%), which was statistically significant